BC Extra | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said co-founder C. Frank Bennett will become CSO, with Eric Swayze succeeding him as SVP of research. Bennett will remain the antisense oligonucleotide company’s franchise leader for neurology drug discovery. Swayze...
BC Extra | Dec 11, 2019
Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

ElevateBio LLC hired Melissa Carpenter as CSO of regenerative medicine, a new position. She was president of her own stem cell research consulting firm. ElevateBio emerged from stealth in May with $150 million in series...
BC Extra | Jun 17, 2019
Company News

BeiGene exploring commercialization options for returned PD-1 inhibitor

After regaining global rights to PD-1 inhibitor tislelizumab from Celgene, BeiGene is exploring options to commercialize the asset on its own or find a partner for the product in the U.S., Europe and Japan. The...
BC Extra | Jun 15, 2019
Company News

June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

ISS weighs in on Weber  Institutional Shareholder Services recommended Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) shareholders oppose President and CEO Christophe Weber at the June 27 shareholder meeting because “top management is responsible for the...
BC Extra | May 14, 2019
Company News

Management tracks: DBV, Beam, Aeon Biopharma

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Deputy CEO and Principal Financial Officer David Schilansky will leave the company in August to pursue other opportunities. The allergy company is searching for a new CFO but will...
BC Extra | Dec 17, 2018
Company News

Management tracks: Vertex’s Graney joins Generation Bio

Tom Graney has left Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) as CFO to take on the same role at non-viral gene therapy company Generation Bio Co. (Cambridge, Mass.). Ian Smith, Vertex EVP and COO and former CFO,...
BC Week In Review | Dec 14, 2018
Company News

Mereo, OncoMed announce merger

Mereo BioPharma Group plc (LSE:MPH) announced a merger with OncoMed Pharmaceuticals Inc. (NASDAQ:OMED); the resulting entity will focus on development of Mereo's orphan disease pipeline and will be listed on London Stock Exchange and NASDAQ....
BioCentury | Nov 17, 2018
Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
BioCentury | Nov 7, 2018
Emerging Company Profile

ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors....
BC Week In Review | Sep 21, 2018
Company News

Ahead of Ph Ib data, Celgene declines to exercise option to OncoMed bispecific

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Sept. 20 that partner Celgene Corp. (NASDAQ:CELG) will not exercise its option to license OncoMed's bispecific antibody navicixizumab (OMP-305B83) as a result of "strategic product portfolio considerations." The bispecific targeting...
Items per page:
1 - 10 of 231
BC Extra | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said co-founder C. Frank Bennett will become CSO, with Eric Swayze succeeding him as SVP of research. Bennett will remain the antisense oligonucleotide company’s franchise leader for neurology drug discovery. Swayze...
BC Extra | Dec 11, 2019
Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

ElevateBio LLC hired Melissa Carpenter as CSO of regenerative medicine, a new position. She was president of her own stem cell research consulting firm. ElevateBio emerged from stealth in May with $150 million in series...
BC Extra | Jun 17, 2019
Company News

BeiGene exploring commercialization options for returned PD-1 inhibitor

After regaining global rights to PD-1 inhibitor tislelizumab from Celgene, BeiGene is exploring options to commercialize the asset on its own or find a partner for the product in the U.S., Europe and Japan. The...
BC Extra | Jun 15, 2019
Company News

June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

ISS weighs in on Weber  Institutional Shareholder Services recommended Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) shareholders oppose President and CEO Christophe Weber at the June 27 shareholder meeting because “top management is responsible for the...
BC Extra | May 14, 2019
Company News

Management tracks: DBV, Beam, Aeon Biopharma

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Deputy CEO and Principal Financial Officer David Schilansky will leave the company in August to pursue other opportunities. The allergy company is searching for a new CFO but will...
BC Extra | Dec 17, 2018
Company News

Management tracks: Vertex’s Graney joins Generation Bio

Tom Graney has left Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) as CFO to take on the same role at non-viral gene therapy company Generation Bio Co. (Cambridge, Mass.). Ian Smith, Vertex EVP and COO and former CFO,...
BC Week In Review | Dec 14, 2018
Company News

Mereo, OncoMed announce merger

Mereo BioPharma Group plc (LSE:MPH) announced a merger with OncoMed Pharmaceuticals Inc. (NASDAQ:OMED); the resulting entity will focus on development of Mereo's orphan disease pipeline and will be listed on London Stock Exchange and NASDAQ....
BioCentury | Nov 17, 2018
Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
BioCentury | Nov 7, 2018
Emerging Company Profile

ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors....
BC Week In Review | Sep 21, 2018
Company News

Ahead of Ph Ib data, Celgene declines to exercise option to OncoMed bispecific

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Sept. 20 that partner Celgene Corp. (NASDAQ:CELG) will not exercise its option to license OncoMed's bispecific antibody navicixizumab (OMP-305B83) as a result of "strategic product portfolio considerations." The bispecific targeting...
Items per page:
1 - 10 of 231